دورية أكاديمية
أعرض في EDS

Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET/RANO group.

التفاصيل البيبلوغرافية
العنوان: Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET/RANO group.
المؤلفون: Galldiks N; Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.; Institute of Neuroscience and Medicine (INM-3, INM-4), Research Center Juelich, Juelich, Germany.; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Germany., Kaufmann TJ; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA., Vollmuth P; Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany.; Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany., Lohmann P; Institute of Neuroscience and Medicine (INM-3, INM-4), Research Center Juelich, Juelich, Germany., Smits M; Department of Radiology and Nuclear Medicine and Brain Tumour Center, Erasmus MC, Rotterdam, The Netherlands., Veronesi MC; Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin, USA., Langen KJ; Institute of Neuroscience and Medicine (INM-3, INM-4), Research Center Juelich, Juelich, Germany.; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Germany.; Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany., Rudà R; Division of Neuro-Oncology, Department of Neuroscience, University of Turin, Turin, Italy., Albert NL; Department of Nuclear Medicine, LMU Hospital, Ludwig Maximilians-University of Munich, Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany., Hattingen E; Goethe University, Department of Neuroradiology, University Hospital Frankfurt, Frankfurt, Germany., Law I; Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark., Hutterer M; Department of Neurology with Acute Geriatrics, Saint John of God Hospital, Linz, Austria., Soffietti R; Division of Neuro-Oncology, Department of Neuroscience, University of Turin, Turin, Italy., Vogelbaum MA; Department of Neuro-Oncology and Neurosurgery, Moffit Cancer Center, Tampa, Florida, USA., Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Weller M; Department of Neurology, Clinical Neuroscience Center, and University Hospital of Zurich, Zurich, Switzerland.; University of Zurich, Zurich, Switzerland., Tonn JC; German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Neurosurgery, University Hospital of Munich (LMU), Munich, Germany.
المصدر: Neuro-oncology [Neuro Oncol] 2024 Jul 05; Vol. 26 (7), pp. 1181-1194.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2010- : Oxford : Oxford University Press
Original Publication: 1999-<2002> : Charlottesville, VA : Carden Jennings Pub.,
مواضيع طبية MeSH: Brain Neoplasms*/diagnostic imaging , Brain Neoplasms*/pathology , Positron-Emission Tomography*/methods , Magnetic Resonance Imaging*/methods, Humans
مستخلص: Brain tumor diagnostics have significantly evolved with the use of positron emission tomography (PET) and advanced magnetic resonance imaging (MRI) techniques. In addition to anatomical MRI, these modalities may provide valuable information for several clinical applications such as differential diagnosis, delineation of tumor extent, prognostication, differentiation between tumor relapse and treatment-related changes, and the evaluation of response to anticancer therapy. In particular, joint recommendations of the Response Assessment in Neuro-Oncology (RANO) Group, the European Association of Neuro-oncology, and major European and American Nuclear Medicine societies highlighted that the additional clinical value of radiolabeled amino acids compared to anatomical MRI alone is outstanding and that its widespread clinical use should be supported. For advanced MRI and its steadily increasing use in clinical practice, the Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition provided more recently an updated acquisition protocol for the widely used dynamic susceptibility contrast perfusion MRI. Besides amino acid PET and perfusion MRI, other PET tracers and advanced MRI techniques (e.g. MR spectroscopy) are of considerable clinical interest and are increasingly integrated into everyday clinical practice. Nevertheless, these modalities have shortcomings which should be considered in clinical routine. This comprehensive review provides an overview of potential challenges, limitations, and pitfalls associated with PET imaging and advanced MRI techniques in patients with gliomas or brain metastases. Despite these issues, PET imaging and advanced MRI techniques continue to play an indispensable role in brain tumor management. Acknowledging and mitigating these challenges through interdisciplinary collaboration, standardized protocols, and continuous innovation will further enhance the utility of these modalities in guiding optimal patient care.
(© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
References: Curr Opin Oncol. 2021 Nov 1;33(6):597-607. (PMID: 34534142)
AJNR Am J Neuroradiol. 2015 Sep;36(9):1654-61. (PMID: 26066626)
AJNR Am J Neuroradiol. 2012 Oct;33(9):1763-70. (PMID: 22538078)
Mol Imaging Biol. 2008 Jan-Feb;10(1):1-18. (PMID: 17957408)
J Nucl Med. 2011 Jun;52(6):856-64. (PMID: 21622893)
Cell Metab. 2015 Aug 4;22(2):304-11. (PMID: 26212717)
Hematol Oncol Clin North Am. 2022 Feb;36(1):43-61. (PMID: 34563433)
Clin Nucl Med. 2023 Apr 1;48(4):e207-e208. (PMID: 36728314)
J Nucl Med. 2006 May;47(5):776-82. (PMID: 16644747)
Nucl Med Biol. 2013 Aug;40(6):795-800. (PMID: 23769262)
Neuro Oncol. 2015 Sep;17(9):1188-98. (PMID: 26250565)
Clin Nucl Med. 2020 Aug;45(8):621-622. (PMID: 32520501)
Eur J Nucl Med Mol Imaging. 2024 Jan;51(2):496-509. (PMID: 37776502)
Mol Imaging Biol. 2020 Oct;22(5):1255-1265. (PMID: 32409931)
Clin Nucl Med. 2018 Nov;43(11):840-841. (PMID: 30179915)
Neuro Oncol. 2022 Sep 1;24(9):1546-1556. (PMID: 35171292)
J Nucl Med. 1994 Jul;35(7):1162-6. (PMID: 8014676)
Nat Rev Neurol. 2021 Aug;17(8):486-500. (PMID: 34149051)
Diagn Interv Imaging. 2014 Oct;95(10):985-1000. (PMID: 25001364)
Clin Imaging. 2022 Dec;92:124-130. (PMID: 36374712)
Ann Nucl Med. 2003 Feb;17(1):47-51. (PMID: 12691130)
Radiother Oncol. 2023 Jul;184:109694. (PMID: 37150450)
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):591-602. (PMID: 30327856)
J Nucl Med. 2013 Feb;54(2):229-35. (PMID: 23232275)
Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):685-95. (PMID: 25411133)
Lancet Digit Health. 2022 Nov;4(11):e841-e849. (PMID: 36182633)
Neuro Oncol. 2016 Sep;18(9):1199-208. (PMID: 27106405)
Lancet Neurol. 2010 Sep;9(9):906-20. (PMID: 20705518)
Neuro Oncol. 2020 Jun 9;22(6):757-772. (PMID: 32048719)
NMR Biomed. 2013 Aug;26(8):913-31. (PMID: 22782914)
Korean J Radiol. 2016 May-Jun;17(3):424-34. (PMID: 27134530)
J Neurol. 2021 Apr;268(4):1266-1275. (PMID: 33084938)
J Neuroradiol. 2009 May;36(2):74-81. (PMID: 18835643)
Semin Nucl Med. 2021 Sep;51(5):408-418. (PMID: 33820651)
J Nucl Med. 2023 May;64(5):816-821. (PMID: 36460343)
Front Neurol. 2022 Mar 30;13:822362. (PMID: 35432168)
Front Oncol. 2021 Mar 30;11:646387. (PMID: 33859946)
Clin Nucl Med. 2021 Jan;46(1):e36-e37. (PMID: 32804767)
J Nucl Med. 2023 Oct;64(10):1594-1602. (PMID: 37562802)
EJNMMI Res. 2017 Dec;7(1):48. (PMID: 28560582)
Neuro Oncol. 2020 Jan 11;22(1):17-30. (PMID: 31437274)
Clin Nucl Med. 2010 Nov;35(11):907-8. (PMID: 20940559)
J Magn Reson Imaging. 2016 Jan;43(1):11-27. (PMID: 25857715)
AJNR Am J Neuroradiol. 2021 Nov;42(11):1920-1926. (PMID: 34446457)
Semin Ultrasound CT MR. 2021 Oct;42(5):452-462. (PMID: 34537114)
Eur Radiol. 2018 Aug;28(8):3306-3317. (PMID: 29536240)
Theranostics. 2019 Jul 9;9(17):5085-5104. (PMID: 31410203)
Clin Nucl Med. 2018 Sep;43(9):e322-e323. (PMID: 30080188)
Neuro Oncol. 2017 Nov 29;19(12):1576-1587. (PMID: 28605532)
Neuro Oncol. 2019 Oct 9;21(10):1331-1338. (PMID: 31077276)
AJNR Am J Neuroradiol. 2002 May;23(5):844-6. (PMID: 12006290)
Neuro Oncol. 2013 Mar;15(3):341-51. (PMID: 23335162)
Neuro Oncol. 2017 Jan;19(1):118-127. (PMID: 27502247)
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):540-557. (PMID: 30519867)
Br J Radiol. 2018 Apr;91(1084):20170847. (PMID: 29271230)
Radiology. 2016 Nov;281(2):337-356. (PMID: 27755938)
Neuroradiology. 2015 Dec;57(12):1181-202. (PMID: 26351201)
AJNR Am J Neuroradiol. 2020 Mar;41(3):408-415. (PMID: 32165359)
Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3852-3869. (PMID: 35536420)
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1423-1431. (PMID: 29523925)
J Nucl Med. 2020 Sep;61(9):1294-1299. (PMID: 32005771)
Neuroimage. 2002 Jan;15(1):175-81. (PMID: 11771986)
Neuro Oncol. 2020 Sep 29;22(9):1262-1275. (PMID: 32516388)
J Nucl Med. 1998 Jun;39(6):974-7. (PMID: 9627328)
J Nucl Med. 1995 Dec;36(12):2175-9. (PMID: 8523100)
NMR Biomed. 2013 Aug;26(8):1004-27. (PMID: 23674304)
Cancers (Basel). 2023 Jul 12;15(14):. (PMID: 37509252)
J Nucl Med. 2020 Apr;61(4):498-504. (PMID: 31541032)
Br J Radiol. 2022 Feb 1;95(1130):20210944. (PMID: 34808072)
J Nucl Med. 2021 Apr;62(4):464-470. (PMID: 32887757)
Prog Nucl Magn Reson Spectrosc. 2018 Dec;109:1-50. (PMID: 30527132)
Neuro Oncol. 2022 Nov 2;24(11):1815-1826. (PMID: 35674736)
Nat Med. 2012 Jan 26;18(4):624-9. (PMID: 22281806)
J Nucl Med. 2010 May;51(5):790-7. (PMID: 20395334)
Radiology. 2000 Nov;217(2):377-84. (PMID: 11058631)
Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1374-80. (PMID: 16932934)
Clin Nucl Med. 2016 Oct;41(10):753-60. (PMID: 27454592)
EJNMMI Res. 2017 Aug 16;7(1):64. (PMID: 28815478)
J Neurosurg. 2005 Feb;102(2):318-27. (PMID: 15739561)
Clin Nucl Med. 2017 Dec;42(12):e506-e508. (PMID: 29076908)
Magn Reson Med. 2019 Aug;82(2):527-550. (PMID: 30919510)
Radiology. 2019 Jun;291(3):752-762. (PMID: 30990380)
Neurooncol Adv. 2019 Oct 20;1(1):vdz038. (PMID: 32642667)
Nat Rev Neurol. 2017 May;13(5):279-289. (PMID: 28387340)
Cancers (Basel). 2019 Jan 29;11(2):. (PMID: 30699942)
NMR Biomed. 2013 Aug;26(8):1042-9. (PMID: 23832526)
J Nucl Med. 2021 Jul 1;62(7):918-925. (PMID: 33158907)
Clin Neurol Neurosurg. 1995 Nov;97(4):349-53. (PMID: 8599907)
Expert Rev Anticancer Ther. 2011 May;11(5):653-6. (PMID: 21554035)
Eur J Nucl Med Mol Imaging. 2015 May;42(6):905-15. (PMID: 25750084)
Neuro Oncol. 2023 Jun 2;25(6):1193-1195. (PMID: 36960770)
J Nucl Med. 2017 Jan;58(1):129-137. (PMID: 27469356)
Radiol Case Rep. 2017 Jan 30;12(2):365-370. (PMID: 28491190)
Lancet Neurol. 2006 Nov;5(11):937-48. (PMID: 17052661)
Neuroradiol J. 2019 Apr;32(2):103-107. (PMID: 30667319)
Lancet Oncol. 2020 Jun;21(6):e317-e329. (PMID: 32502458)
Clin Cancer Res. 2021 Jul 1;27(13):3704-3713. (PMID: 33947699)
Nucl Med Biol. 2006 Nov;33(8):1029-35. (PMID: 17127177)
AJNR Am J Neuroradiol. 2020 Nov;41(11):2049-2054. (PMID: 33060101)
Neuro Oncol. 2019 Dec 17;21(12):1595-1606. (PMID: 31618420)
Front Oncol. 2023 Aug 24;13:1254674. (PMID: 37692853)
Ann Nucl Med. 2002 May;16(3):207-11. (PMID: 12126046)
فهرسة مساهمة: Keywords: CEST; MR spectroscopy; amino acid PET; diffusion-weighted imaging; perfusion-weighted imaging
تواريخ الأحداث: Date Created: 20240311 Date Completed: 20240706 Latest Revision: 20240708
رمز التحديث: 20240708
مُعرف محوري في PubMed: PMC11226881
DOI: 10.1093/neuonc/noae049
PMID: 38466087
قاعدة البيانات: MEDLINE
الوصف
تدمد:1523-5866
DOI:10.1093/neuonc/noae049